Richard Fessler, MD, on OPC1 Improving Quality of Life With Spinal Cord Injury

Commentary
Video

The professor of neurosurgery at Rush University Medical School discussed follow-up in the phase 1/2 trial of LCTOPC1 and further research to be done.

“Fifty percent of individuals with spinal cord injury, at some point in their life will have a fracture. And that's because their bones become demineralized. So, we're trying to figure out why, and what we can do to stop that, so that we can minimize fractures in these patients. So,they're living normal life expectancy now, but we want to give them as good a quality of life as we potentially can.”

Lineage Cell Therapeutics’ oligodendrocyte progenitor cell therapy candidate OPC1 has shown good safety and promising efficacy in patients with spinal cord injury (SCI) and is continuing to be evaluated in long-term follow-up of a phase 1/2 trial (NCT02302157). The company plans to meet with the FDA this year in a Type B Meeting to discuss a proposed amendment to the Investigational New Drug application (IND) for OPC1 to enable clinical testing of a novel spinal cord delivery system.

CGTLive spoke with the study’s primary investigator, Richard Fessler, MD, a professor of neurosurgery at Rush University Medical School, to learn more about the trial. He talked about 10-year follow-up data that have recently been published which showed no serious adverse events of interest in the treated patients and quality-of-life improvements after treatment with OPC1. He also shared his experiences with keeping up with these patients, who he called inspirational, over the last 10 years and being able to see these improvements and keep up with their lives.

REFERENCE
Lineage Cell Therapeutics reports first quarter 2023 financial results and provides business update. News release. Lineage Cell Therapeutics. May 11, 2023. https://www.businesswire.com/news/home/20230511005135/en/Lineage-Cell-Therapeutics-Reports-First-Quarter-2023-Financial-Results-and-Provides-Business-Update
Recent Videos
David Barrett, JD, the chief executive officer of ASGCT
David-Alexandre C. Gros, MD, Eledon’s chief executive officer
David Barrett, JD, the chief executive officer of ASGCT
Alfred L. Garfall, MD, MS, associate professor of medicine (hematology-oncology) and director, Autologous Hematopoietic Cell Transplantation, Cell Therapy and Transplant Program, Hospital of the University of Pennsylvania; and section chief, Multiple Myeloma, Division of Hematology/Oncology, Department of Medicine, Perelman School of Medicine, University of Pennsylvania,
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Nirav Shah, MD, MSHP, associate professor of medicine, at the Medical College of Wisconsin
Bhagirathbhai R. Dholaria, MD, an associate professor of medicine in malignant hematology & stem cell transplantation at Vanderbilt University Medical Center
Reena Sharma, MD, an adult metabolic consultant at Salford Royal Hospital
Mark Hamilton, MD, PhD, a hematology-oncology and bone marrow transplant (BMT) cell therapy fellow at Stanford University
Barry J Byrne, MD, PhD, the chief medical advisor of MDA and a physician-scientist at the University of Florida
Related Content
© 2025 MJH Life Sciences

All rights reserved.